Media Center

CLSI 2019 Q4 CONNECTIONS – Read More


FAST Companies

  • Fauna Bio (FAST Spring ’19) was awarded a Phase I Small Business Innovation Research (SBIR) grant from the National Institutes of Health (NIH) for the development of its integrated genomics platform and testing of repurposed drug candidates Read More
  • Atropos Therapeutics (FAST Spring ’18) and Atomwise launched a joint venture to discover and advance a pipeline of compounds for promising discovery targets using senescence assay and AI technologies for the treatment of cancer Read More
  • Raydiant Oximetry (FAST Spring ‘17) raised a $5.6 million Series A fund Read More
  • Encellin (FAST Spring ’17) featured in FierceBiotech news: “Y Combinator startup pursuing ‘scarless’ pouch for cell transplants in diabetes.” Read More
  • Inflammatix (FAST Fall ‘17) inked a contract worth up to $72M with BARDA to further develop and commercialize its sample-to-answer HostDx molecular testing system Read More
  • Eidos Therapeutics (FAST Spring ’16) and Alexion Pharmaceuticals announced an agreement to grant Alexion an exclusive license to develop and commercialize AG10 for transthyretin amyloidosis (ATTR) in Japan Read More
  • Paragon Genomics (FAST Spring ‘16) introduces two new products — CleanPlex® CFTR Panel for cystic fibrosis and CleanPlex Fusion Detection Methods for the diagnostic and prognostic assessment of cancer tumor progression Read More
  • Shasqi (FAST Spring ’16) announced the completion of a $10 million Series A financing Read More
  • Magnetic Insight (FAST Spring ‘15) introduced the first commercially available magnetic particle imaging (MPI) system with integrated X-ray computed tomography (CT) Read More
  • Xcell Biosciences (FAST Fall ’13) CEO Brian Feth took first place at the World Alliance Forum Healthcare Game Changers Startup Pitch competition, one of five companies to pitch in front of 300 investors and business executives from the U.S. and Japan.


  • CARB-X funds SutroVax to develop a new vaccine to prevent Group A Streptococcal infections Read More
  • CARB-X strengthens leadership team with appointment of Erin Duffy as Chief of Research and Development (R&D) Read More
  • 2018-19 Annual Report: Progress in CARB-X’s fight against drug-resistant bacteria with new funding, expertise and strategic focus Read More
  • CARB-X funds Procarta Biosystems to develop oligonucleotide-based antibiotics to combat life-threatening Gram-negative pathogens Read More
  • CARB-X funds BioVersys to support the development of first-in-class anti-virulence small molecule drugs designed to disarm bacteria Read More
  • CARB-X funds Techulon to support the development of innovative nano therapeutics capable of killing drug-resistant bacteria by precisely targeting essential genes Read More
  • CARB-X funds VenatoRx Pharmaceuticals to support the development of a new class of oral antibiotics to treat multi-drug-resistant gonorrhea Read More
  • CARB-X funds Vedanta Biosciences to accelerate the development of a new category of oral therapeutics to help a patient’s microbiota fight drug-resistant bacteria Read More


CLSI/CLSA events

  • 1/15 | San Francisco, CLSA Reception at JP Morgan Healthcare Conference (Invitation Only)
  • 1/21 | San Francisco, CLSI Startup Buzz Networking Event

Community Events

  • 1/1 | Berkeley, CITRIS Foundry Incubator Spring 2020 Application Deadline
  • 1/8 | Berkeley, Berkeley SkyDeck Spring 2020 Cohort Application Deadline
  • 1/11 | San Francisco, DOCSF Conference
  • 1/12 | San Francisco, Pre-JPM CTIC 4th Healthcare Investment Summit
  • 1/13 | San Francisco, UCSF Health Hub: The Next Generation of Digital Health: Israel’s Innovation for the Future
  • 1/13 | San Francisco, Health 2.0 Venture Connect Startup Showcase
  • 1/13-14 | San Francisco, StartUp Health Festival
  • 1/15 | San Francisco, T3 Advisors and Biolabs JPM 2020 Lunch and Learn: A Panel Discussion on Lab Space
  • 1/17 | South San Francisco, JLABS: Meet with National Institute on Drug Abuse
  • 1/21-24 | Santa Clara, Precision Medicine World Conference 2020
  • 1/23 | San Francisco, LaunchBio: Larger than Life Science
  • 1/30 | South San Francisco, JLABS: Meet with Johnson & Johnson Innovation – JJDC
  • 2/6 | San Francisco, IndieBio Demo Day
  • 2/12 | South San Francisco, JLABS: Meet with Gates Foundation Venture Capital
  • 2/19 | San Francisco, UCSF Health Hub: Reimbursement for Entrepreneurs
  • 3/12 | San Francisco, Leaders in Life Science: George Scangos, CEO, Vir Biotechnology
  • 3/25 | San Francisco, UCSF Health Hub: Invent Health: The Future of Behavioral and Mental Health